Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, multinational, non-randomized, non-controlled open-label phase II
trial to evaluate the safety and efficacy of treosulfan in a combination regimen with
fludarabine as conditioning therapy prior to allogeneic stem cell transplantation (SCT) in
patients with MDS.
The aim is to demonstrate a clinical benefit compared to historical data with intravenous
busulfan.